TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Research  »  Epilepsy Therapy Screening Program (ETSP)  » 

Skip secondary menu

Epilepsy Therapy Screening Program (ETSP)
(previously known as the Anticonvulsant Screening Program, ASP)


Reports on the ASP from NANDS Council Working Groups

May 2015

February 2012

Public Access to Neuroactive & Anticonvulsant Chemical Evaluations - banner
Contacts

John Kehne, Ph.D.
Program Director
john.kehne@nih.gov

Karrah Benson
Program Coordinator
karrah.benson@nih
.gov

Brian Klein, Ph.D.
Scientific Project Manager
brian.klein@nih.gov

Shamsi Raeissi, Ph.D.
Scientific Project Manager
shamsi.raeissi@nih.gov

Shalini Sharma
Program Analyst
Shalini.Sharma@nih.gov

Dhananjaya Kempegowda
IT Support
Dhananjaya.Kempegowda
@nih.gov

Resource Links  
Meetings and Conferences

American Epilepsy Society (AES)

The Epilepsy Foundation

Overview

The mission of the NINDS Epilepsy Therapy Screening Program (ETSP) is to encourage and facilitate the discovery of new therapeutic agents for the treatment of epilepsy disorders. The program provides opportunities for researchers from academia and industry in the U.S. and abroad to submit compounds for screening in a battery of well-established rodent seizure models. These tests are performed at a contract facility based at the University of Utah on a blinded and confidential basis and at no cost to the ETSP participants. The NINDS ETSP staff reports test results to participants and provides advice on next steps for promising compounds. Since its establishment in 1975, the program has made important contributions to the development of several FDA-approved drugs for epilepsy, including felbamate (Felbatol), topirimate (Topamax), lacosamide (Vimpat), and retigabine (Potiga). Historically, the ETSP has focused on identifying symptomatic treatments for seizure disorders, but based on recent recommendations from working groups of the National Advisory Neurological Disorders and Stroke (NANDS) Council, the program is placing emphasis on refractory epilepsy, epileptogenesis and disease progression, special epilepsy populations, and epilepsy comorbidities. Other key recommendations implemented include forming an External Consultant Board (ECB) to provide regular feedback to the ETSP and changing the name of the program to reflect the emphasis on identifying differentiated agents to address the unmet medical needs of epilepsy.

PANAChE Database

A web-based research tool called PANAChE (Public Access to Neuroactive & Anticonvulsant Chemical Evaluations) provides open access to nonproprietary chemical structures and biological data for compounds previously screened in the ETSP, including antiseizure drugs (ASDs) as well as drugs used for other indications. This database is being populated beginning with known drugs in the public domain and only those ETSP compounds that are approved by the participant. PANAChE is also a repository for information on the animal models and assays currently or historically used in the ETSP.

Collapsable minus sign. When the image is clicked on the exposed links that are in bulleted fashion will be hidden. Description of Testing Services

Collapsable minus sign. When the image is clicked on the exposed links that are in bulleted fashion will be hidden. How to Participate

Collapsable minus sign. When the image is clicked on the exposed links that are in bulleted fashion will be hidden. Confidentiality

Last Modified September 8, 2016